Amber Bio, a San Francisco, CA-based developer of multi-kilobase gene editing platforms to reach previously undruggable diseases, launched with a $26m seed financing round.
The round was co-led by Playground Global and Andreessen Horowitz Bio + Health with participation from Eli Lilly, RDF (Retinal Degeneration Fund), Hummingbird Ventures, and Pillar VC.
The company intends to use the funds to advance a first-of-its-kind RNA editing platform which enables multi-kilobase edits, allowing a single drug to treat diseases with high allelic diversity.
Co-Founded by Jacob Borrajo, Ph.D., CEO, and Basem Al-Shayeb, Ph.D., CTO, Amber Bio is pioneering new gene editing modalities using multi-kilobase RNA writing to reach previously undruggable diseases. The company is developing a first-of-its-kind RNA editing platform that can correct genetic mutations in a safe and reversible way.
FinSMEs
03/08/2023